Plasma volume changes may mediate effects of empagliflozin
(HealthDay)—The reduction in risk of cardiovascular (CV) death with empagliflozin is most mediated by changes in hematocrit and hemoglobin, according to research published online Dec. 4 in Diabetes Care.
Dec 26, 2017
0
6